期刊文献+

大豆异黄酮对冠心病患者血脂达标率的影响 被引量:6

Effects of soy isoflavones on success rate for dislipidaemia in patients with coronary heart disease
下载PDF
导出
摘要 目的 观察大豆异黄酮治疗冠心病伴高胆固醇血症患者的疗效 ,及其对血脂达标率的影响。方法 将 78例冠心病伴高胆固醇血症患者随机分为三组 ,各组 2 6例 ,每天分别给予辛伐他汀 2 0mg(辛伐他汀组 )、大豆异黄酮 15 0mg(异黄酮组 ) ,二药合用组 ,疗程为 8周。结果 辛伐他汀、大豆异黄酮均降低总胆固醇 (TC)、低密度脂蛋白 胆固醇 (LDL C)载脂蛋白B10 0 (ApoB10 0 )和脂蛋白 (a) [Lp(a) ] (P <0 .0 5及 0 .0 1) ;二药合用组TC、LDL C、降低效果明显优于各自单用药组 ,达标率明显提高 ( 69%比 2 3 %、19% ,P <0 .0 1) ,血清甘油三酯 (TG)降低 ,高密度脂蛋白 胆固醇 (HDL C)、载脂蛋白A1(ApoA1)升高 (P <0 .0 1)。结论 大豆异黄酮全面改善血脂 ,与他汀类合用效果更显著 ,并大幅度提高达标率。 Objective To observe the curative effect of isoflavones on dislipidaemia and success rate in patients with coronary heart disease(CHD).Methods 78 hypercholesterolaemia patients with CHD were randomly into three groups(n=26 for each group),received therapy with simvastatin 20mg/d,isoflavones 150mg/d alone or together,respectively.The therapy continued for 8 weeks.Results After therapy with isoflavones or simvastatin alone, total cholesterol(TC)、low density lipoprotein cholesterol(LDL-C)、apoprotein B100(ApoB100)、lipoprotein (a)[Lp(a)] were decreased(P<0.05 and 0.01).The decrease in TC、LDL-C were superior and success rate was increased remarkably while therapy together,compared with isoflavones or simvastatin alone (69% vs 23%、19%,P<0.01).Besides,triglyceride(TG) was decreased、high density lipoprotein cholesterol(HDL-C) and apoprotein A1(ApoA1) increased(P<0.01).Conclusion Isoflavones improve dislipidaemia generally in patients with CHD.When combined with simvastatin therapy,the curative effect and success rate is remarkably superior to isoflavones or simvastatin alone.
出处 《临床内科杂志》 CAS 北大核心 2004年第6期393-394,共2页 Journal of Clinical Internal Medicine
基金 广东省韶关市科委重点科技资助项目 (Y2 0 0 30 31 7)
关键词 高胆固醇血症 冠状动脉疾病 辛伐他汀 异黄酮 Hypercholesterolaemia Coronary artery disease Simvastatin Isoflavones
  • 相关文献

参考文献5

二级参考文献11

  • 1Slamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol a nd risk of premature death from coronary heart disease continuous and graded ? F indings in 356,222 primary screenees of the Multiple Risk Factor Intervention Tr ial (MRFIT). JAMA, 1986,256:2823-2828.
  • 2Castelli WP, Garrison RJ,Wilson PwF, et al. Incidence of coronary heart disea se and lipoprotein cholesterol levels: the Framing ham Study. JAMA, 1986, 256:28 35-2838.
  • 3Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S).Lancet,1994,344:1383 -1389.
  • 4Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary- prevention t ri al with gemfibrozil in middle-aged men with dislipidemia. Safety of treatment ,c hages in risk factors, and incidence of coronary heart disease. N Engl J Med, 1 987,317:1237-1245.
  • 5Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease wit h pravastatin in men with hypercholesterolemia. West of Scotland Coronary Preven tion Study Group. N Engl J Med,1995,333:1301-1307.
  • 6Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary e v ents with lovastatin in men and women with average cholesterol levels: results o f AFCAPS/TexCAPS. Air Force/Texas Coronary Artherosclerosis Prevention Study. JAMA .1998;279:1615-1622.
  • 7Summary of the second report of the National Cholesterol Education Program (NC EP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholestero l in Adults ( Adult Treatment Panel II Report). JAMA, 1993, 269:3015-3023.
  • 8Report of the National Cholesterol Education Program Expert Panel on Detection , Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Pan el. Arch Intern Med, 1998, 148:36-69.
  • 90 Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L -TAP):a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein choles terol goals. Arch Intern Med, 2000, 160:459-467.
  • 10方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067

共引文献182

同被引文献89

引证文献6

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部